Tuesday, December 27, 2022 8:56:06 AM
Announces $7.5 Million Special Dividend and Contingent Value Right (CVR)
On December 26, 2022, Catalyst Biosciences, Inc., a Delaware corporation (?Catalyst?), acquired the F351 Assets (as defined below) from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (?GNI Japan?), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (?GNI Hong Kong? and, together with GNI Japan, the ?Sellers?), pursuant to that certain Asset Purchase Agreement, dated December 26 2022 (the ?F351 Agreement?), by and among Catalyst and the Sellers. Pursuant to the F351 Agreement, Catalyst acquired all of the assets and intellectual property rights primarily related to the Sellers? proprietary Hydronidone compound (collectively, the ?F351 Assets?), other than such assets and intellectual property rights located in the People?s Republic of China. The F351 Assets include 15 issued or pending patents and patent applications outside of the People?s Republic of China, with the last acquired issued patent expected to expire in August 2037.
Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement (the ?F351 Effective Time?), Catalyst paid the Sellers $35,000,000 in the form of: 6,266,521 shares of Catalyst common stock, par value $0.001 per share (the ?Catalyst Common Stock?); and 12,340 shares of Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the ?Catalyst Convertible Preferred Stock? and collectively with the Catalyst Common Stock issued pursuant to the F351 Agreement, the ?Catalyst F351 Securities?).
Each of Catalyst and the Sellers has agreed to customary representations, warranties and covenants in the F351 Agreement, including, among others, covenants relating to (1) Catalyst filing with the U.S. Securities and Exchange Commission (the ?SEC?) and causing to become effective a registration statement (the ?Registration Statement?) to register (a) the shares of Catalyst Common Stock issued pursuant to the F351 Agreement, and (b) the shares of Catalyst Common Stock reserved for issuance upon conversion of the Catalyst Convertible Preferred Stock, (2) Catalyst using reasonable best efforts to maintain the existing listing of the Catalyst Common Stock on The Nasdaq Stock Market LLC (?Nasdaq?) and Catalyst causing the (a) shares of Catalyst Common Stock issued in connection with the F351 Agreement and (b) the shares of Catalyst Common Stock reserved for issuance upon conversion of the Catalyst Convertible Preferred Stock, to be approved for listing on Nasdaq, and (3) the Sellers assuming and paying, discharging, performing or otherwise satisfying the liabilities and obligations of any kind and nature relating to the Purchased Contracts (as defined in the F351 Agreement).
Recent CBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2024 10:19:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2024 08:51:43 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2024 12:49:16 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 12:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2024 12:46:38 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/19/2024 08:06:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/09/2024 08:31:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/08/2024 10:03:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/05/2024 09:40:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/04/2024 09:27:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/03/2024 08:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2024 08:01:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2024 09:35:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2024 10:42:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 09:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 01:55:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:31:12 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:27:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/21/2024 11:15:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2024 08:47:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/15/2024 09:29:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:16:03 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:11:14 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/19/2024 09:05:30 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/12/2024 09:01:35 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM